🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07111169
Recruiting Not applicable

Neuromodulation and Attention Deficits in MDD

NCT07111169 · tracked via the Priya Life Science China tracker
Sponsor
University of Electronic Science and Technology of China
Phase
Not applicable
Started
2024-01-01
Last updated
2025-08-08

Condition(s) studied

Major Depression DisorderCognitive DeficitsSelective Attention

Investigational drug(s) / intervention(s)

intermittent theta burst stimulation (iTBS) intervention

intermittent theta burst stimulation (iTBS) intervention: iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.

Study summary

Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC) stimulation enhances cognitive control and modulates maladaptive attention processes in MDD and whether the effects are influenced by neuronavigated versus manual (Beam F3 method) localization of the stimulation site.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * 18-55 years * Right-handed * Normal or corrected normal visual acuity * MDD: meet the proposed DSM-5 MDD criteria, unmedicated or stable medicated within the last one month. Healthy subjects without any past or present psychiatric or neurological disorders. Exclusion Criteria: * Diagnosis of other severe mental disorders, such as schizophrenia, bipolar disorder, neurodevelopmental disorder, etc. * high suicidal risk * Unnormal intellectual functioning, auditory impairments, * Have received neuromodulation, such as Modified Electroconvulsive Therapy (MECT), or any psychotherapy within the past 6 months. * Only for the active-iTBS group: have a contraindication to MRI scanning (e.g., metal implants, claustrophobia or other conditions that make them inappropriate for MRI scanning).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Clinical Hospital of Chengdu Brain Science Institute, Chengdu Fourth People's Hospital, Jiujiang Branch (Chengdu Mental Health Center) Chengdu Sichuan Recruiting

More University of Electronic Science and Technology of China trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07111169 on ClinicalTrials.gov ↗ ← All trials in China